FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 630 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide December 5, 2025 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Summer Sun Safety Tips September 3, 2020 AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 Load more HOT NEWS How erectile dysfunction drugs could be the key to overcoming treatment... EMA Recommends Granting a Marketing Authorisation for Azacitidine Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the...
